Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;7(Suppl 2):S134-S137.
doi: 10.21037/tlcr.2018.03.08.

The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Lore Decoster  1 , Philippe Giron  1 , Sacha Mignon  1 , Jacques De Grève  1
Affiliations
Editorial

The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Lore Decoster et al. Transl Lung Cancer Res. 2018 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2017;35:3484-515. 10.1200/JCO.2017.74.6065 - DOI - PubMed
    1. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27. 10.1093/annonc/mdw326 - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib of carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study. Lancet Oncol 2011;12:735-42. 10.1016/S1470-2045(11)70184-X - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed